New York Times - Apr 30, 2009Allergan, Inc. (AGN)
-
David Steinberg
at
Deutsche BankIn the United States, "it's essentially been - what - an 18 year monopoly for Botox?" said David M. Steinberg, an analyst at Deutsche Bank . In the absence of serious competition,
Allergan had been able to raise the drug's price annually. But Dysport, which in Europe has been priced lower than Botox, has the potential to capture up to 20 percent of the market in this country he said. "Many doctors have been clamoring for another option," Mr. Steinberg said. Injectable botulinum toxins are purified forms of the bacterial poison that causes botulism , a paralyzing disease that can be fatal.
Share:
<span class="sent">In the United States, "it's essentially been - what - an 18 year monopoly for Botox?" said <span class="analyst">David M. Steinberg</span>, an analyst at Deutsche Bank . </span> In the absence of serious competition, <span class="company">Allergan</span> had been able to raise the drug's price annually. But Dysport, which in Europe has been priced lower than Botox, has the potential to capture up to 20 percent of the market in this country he said. "Many doctors have been clamoring for another option," Mr. Steinberg said. Injectable botulinum toxins are purified forms of the bacterial poison that causes botulism , a paralyzing disease that can be fatal.
Tweet this